Abstract Search

ISEF | Projects Database | Finalist Abstract

Back to Search Results | Print PDF

TETEBENE: Effects of the Experimental Therapeutic Model Isolated Peptide Toxic-prodrug in the Treatment of Subjects with Breast Cancer and with/without Diabetes

Booth Id:



Finalist Names:
Rodriguez Fajardo, Demetrio

Currently breast cancer and complications for Diabetes are the two major public health problems in Latin America. It is estmated that onde of every ten women and one in every hundred men have breast cancer; a fact that becomes more complex when a patient with diabetes are in a oncological treatment;because chemotherapy drugs and radiaton used in these processes produce a more uncontrolled glucose levels in the endocrine patient. Additionally oncological treatments are too expensive, ineffective and require a lot of medical personnel are not always available to the population that needs them. This research has resulted in the discovery of a peptide capable of inhibiting tumor cell growth, retarding the growth of murine tumors and generate an anti-inflammatory and analgesic effect, this peptide is located in the venom of two different species of scorpions, the Centruroiudes suffusus and the Rhopalurus Junceus. The purpose of this project was to design a completely new treatment for people with breast cancer based on the peptide from the venom of the scorpions suffusus, junceus, and two prodrugs (Cyclophosphamide, Traztazumab); that under certain indication of the Mexican population; studies over fifteen months on the human tumor cell lines MCF-7, T47D and HeLa and analysis on animal test subjects have shown that TETEBENE as it has bee referred to the mixture;has an average inhibition of tumor cell growth four to five times larger and a mechanism of action less harmful to the existing market; mechanism characterized by descomposiocion of active ingredients in hydroxylated intermediates,DNA junctions and antineoplastic effects on cells exhibiting overexpression of HER2.